Gabriel Hortobagyi

Gabriel Hortobagyi is a giant of breast oncology who has contributed landmark research on hormone receptor-positive advanced breast cancer over five decades. He led the pivotal MONALEESA trials of ribociclib combined with endocrine therapy, providing the highest-quality survival evidence for CDK4/6 inhibitors. His clinical trial contributions span from early aromatase inhibitor development to modern targeted therapy combinations. He has chaired ASCO's Board of Directors and has been recognized with virtually every major award in oncology.